Xeris Biopharma Holdings, Inc. (XERS) financial statements and ratios from SEC XBRL: revenue $0.3B (TTM), net margin 0.2%, revenue growth 43.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $291.85M |
| Revenue (TTM) | $0.3B |
| Net Margin | 0.2% |
| Operating Margin (TTM) | 11.4% |
| Net Debt / EBITDA | 2.8 |
| Revenue Growth (YoY) | 43.7% |
| EPS Growth (YoY) | -100.0% |
| EV / EBITDA | 87.7 |
| Price / Book | 115.31 |
| Price / Sales | 5.19 |
| Altman Z-Score | 1.36 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
XERS overview · XERS earnings · XERS KPIs · XERS documents · XERS ownership · XERS peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.